吉非替尼
PTEN公司
体内
心脏毒性
蛋白激酶B
自噬
化学
癌症研究
PI3K/AKT/mTOR通路
药理学
信号转导
生物
细胞凋亡
表皮生长因子受体
生物化学
毒性
受体
生物技术
有机化学
作者
Ali Alhoshani,Fawaz E. Alanazi,Moureq Rashed Alotaibi,Mohamed W. Attwa,Adnan A. Kadi,Abdullah Al‐Dhfyan,Sabah Akhtar,Shireen Hourani,Abdelali Agouni,Asad Zeidan,Hesham Mohamed Korashy
标识
DOI:10.1021/acs.chemrestox.0c00005
摘要
Gefitinib (GEF) is a selective inhibitor of the epidermal growth factor receptor (EGFR) used to treat non-small cell lung cancer. Yet, few cases of cardiotoxicity have been reported. However, the role of the PTEN/Akt/FoxO3a pathway, which mediates GEF anticancer activity, in GEF cardiotoxicity remains unclear. For this purpose, in vitro H9c2 cells and in vivo rat cardiomyocytes were utilized as study models. Treatment of H9c2 cells and Sprague–Dawley rats with GEF significantly induced the expression of hypertrophic and apoptotic markers at mRNA and protein levels with an increased plasma level of troponin. This was accompanied by induction of autophagy and mitochondrial dysfunction in H9c2 cells. Inhibition of cardiac EGFR activity and Akt cellular content of in vitro and in vivo rat cardiomyocytes by GEF increased PTEN and FoxO3a gene expression and cellular content. Importantly, treatment of H9c2 cells with PI3K/Akt inhibitor increased PTEN and FoxO3a mRNA expression associated with potentiation of GEF cardiotoxicity. In addition, by using LC-MS/MS, we showed that GEF is metabolized in the rat heart microsomes into one cyanide- and two methoxylamine-adduct reactive metabolites, where their formation was entirely blocked by CYP1A1 inhibitor, α-naphthoflavone. The current study concludes that GEF induces cardiotoxicity through modulating the expression and function of the cardiac PTEN/AKT/FoxO3a pathway and the formation of CYP1A1-mediated reactive metabolites.
科研通智能强力驱动
Strongly Powered by AbleSci AI